The rich research portfolio of the Monell Chemical Senses Center on sweet taste goes way back: Monell scientists were one of ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 ...

Pharmacokinetics and other pharmacodynamic effects of CT-388 were also assessed. CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib ...

One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent ...

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in ...

Mizuho analysts are betting the stock of the small biotech Terns Pharmaceuticals Inc. could rally sharply if the company’s ...

VK2735 is Viking's GLP-1 agonist, and it has achieved strong results in clinical trials. Participants in a phase 2 trial who ...

Viking Therapeutics (VKTX) stock falls after Roche (RHHBY) posted promising Phase 1 results for its experimental obesity ...

NurPhoto/Getty Images Semaglutide is commonly used to treat type 2 diabetes and aid weight loss, but scientists are also ...